Hidden Heart Risk Revealed: New Non-Profit Empowers Approximately 30% of Americans at Risk for Cardiovascular Disease to Be Advocates for Their Heart Health

SAN FRANCISCO, CA--(Marketwired - November 16, 2013) - Cardiovascular disease is the #1 killer of Americans, yet 50% of hospital admissions for coronary artery disease have normal LDL-cholesterol(i). The Lipoprotein(a) Foundation is revealing this hidden risk for patients.

"Patients with elevated Lipoprotein(a) [Lp(a)] levels have an increased risk of cardiovascular disease, including heart attack, stroke and peripheral arterial disease(ii). Lp(a) is a genetically-determined condition that is not responsive to lifestyle changes. Elevated Lp(a) levels are present in about 30% of the population at large(iii). Since Lp(a) is not currently routinely measured by physicians, many patients are unaware that they have elevated levels. Lp(a) can be measured with a routine lipid blood panel, but there is no adequate treatment currently to lower levels. Knowledge of elevated Lp(a) levels may motivate physicians to treat their patients' risk factors more aggressively and patients to live a heart healthy lifestyle until specific therapies can be developed and tested clinically," said Sotirios Tsimikas, M.D., Professor of Medicine and Director of Vascular Medicine at the University of California San Diego. "The Lipoprotein(a) Foundation is a needed resource for education of patients and their families that aims to raise public awareness of the potential risk of elevated Lp(a) levels that will hopefully lead to prevention and early treatment of cardiovascular disease."

"It is now documented that elevated Lp(a) levels not only cause heart attacks, but also aortic valve stenosis, another serious and potentially deadly heart disease. Therefore like those with heart attacks, individuals with aortic valve stenosis and their family members should have Lp(a) measured," said Professor, Chief Physician Børge Nordestgaard from Copenhagen University Hospital in Denmark. He adds "it is a great commitment to initiate the Lipoprotein(a) Foundation, as this may help more individuals and patients being diagnosed with this genetic disorder."(iv)

"Lipoprotein(a) is the most atherogenic lipoprotein in human blood (a substance promoting the formation of fatty plaques in the arteries). It packs a triple threat: (1) It has the bad properties of low density lipoprotein (LDL), (2) It is an inhibitor of fibrinolysis, a process that prevents blood clots from growing and becoming problematic and (3) It serves as a sink (transporter) for oxidized phospholipids," said Joe McConnell, Ph.D., D.A.B.C.C., Chief Laboratory Officer and co-founder of Health Diagnostics Laboratory, Inc.